729 related articles for article (PubMed ID: 25250517)
1. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
2. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
[TBL] [Abstract][Full Text] [Related]
4. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
5. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM).
Ayalasomayajula SP; Ashton P; Kompella UB
J Ocul Pharmacol Ther; 2009 Apr; 25(2):97-103. PubMed ID: 19284324
[TBL] [Abstract][Full Text] [Related]
6. Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D; Mohaghegh M
J Biomol Screen; 2014 Apr; 19(4):547-55. PubMed ID: 24297044
[TBL] [Abstract][Full Text] [Related]
7. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study.
Cao W; Li H; Zhang J; Li D; Acheampong DO; Chen Z; Wang M
Protein Expr Purif; 2013 Aug; 90(2):55-66. PubMed ID: 23680780
[TBL] [Abstract][Full Text] [Related]
8. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
9. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.
Zhang J; Li H; Wang X; Qi H; Miao X; Zhang T; Chen G; Wang M
Biotechnol Prog; 2012 Jul; 28(4):981-9. PubMed ID: 22581629
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.
Li H; Cao W; Chen Z; Acheampong DO; Jin H; Li D; Zhang J; Wang M
Biomed Pharmacother; 2013 Sep; 67(7):599-606. PubMed ID: 23906761
[TBL] [Abstract][Full Text] [Related]
11. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
[TBL] [Abstract][Full Text] [Related]
12. Ultrastrong trapping of VEGF by graphene oxide: Anti-angiogenesis application.
Lai PX; Chen CW; Wei SC; Lin TY; Jian HJ; Lai IP; Mao JY; Hsu PH; Lin HJ; Tzou WS; Chen SY; Harroun SG; Lai JY; Huang CC
Biomaterials; 2016 Dec; 109():12-22. PubMed ID: 27639528
[TBL] [Abstract][Full Text] [Related]
13. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
14. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
15. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
16. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
[TBL] [Abstract][Full Text] [Related]
17. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
[TBL] [Abstract][Full Text] [Related]
18. A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo.
Kim Y; Jung HJ; Kwon HJ
Biochem Biophys Res Commun; 2012 Jan; 417(1):330-4. PubMed ID: 22155252
[TBL] [Abstract][Full Text] [Related]
19. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
20. Identification of a neutralizing scFv binding to human vascular endothelial growth factor 165 (VEGF165) using a phage display antibody library.
Lin Z; Cao P; Lei H
Appl Biochem Biotechnol; 2008 Jan; 144(1):15-26. PubMed ID: 18415983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
